LISATA THERAPEUTICS, INC. — Director's Dealing 2017

Jan 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-01-09

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-09	Common Stock	A	33300	—	Acquired	80538	Direct
2017-01-09	Common Stock	F	4758	$3.54	Disposed	75780	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-09	Stock Option	$3.54	A	50000	Acquired	2027-01-09	Common Stock (50000)	Direct

Footnotes

F1: Represents 33,300 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan. 25% of the shares of restricted stock vest immediately on the grant date and the remaining 75% of the shares of restricted stock will vest annually over the following three years.

F2: Includes 39,943 shares of unvested restricted stock.

F3: 25% of the shares underlying the stock options vest immediately on the grant date and the remaining 75% of the shares underlying the stock options will vest annually over the following three years.